Loading...
ESMO congress Lung Cancer 20202025-01-28T17:08:43+01:00

ESMO 2020 – Congress digest on Lung Cancer – virtual

Lecture Board: Paul Baas, MD, PhD; Byoung Chul Cho, MD, PhD; Maximilian Hochmair, MD; Maarten Lambrecht, MD, PhD
Medical Writer: Dr. Judith Moser

DOWNLOADS

All downloads from ESMO 2020 Lung Cancer – virtual

ESMO 2020 Lung Cancer English Slide Kit

Slide Kit PD-1/PD-L1 and PARP inhibition in NSCLC

ESMO 2020 Lung Cancer English

Full report (english)

ESMO 2020 Lung Cancer Mandarin

Full report (mandarin)

ESMO 2020 Lung Cancer Japanese

Full report (japanese)

EXPERT VIDEOS

All video interviews from ESMO Lung Cancer 2020

Tony Mok summarizes insights into the immunotherapeutic management of patients with advanced lung cancer who receive PD-1 inhibitors and relates to aspects of biomarker-based treatment selection, patient prognosis, and new agents that might change the treatment landscape.

Byoung Chul Cho explains about the rationale and outcomes for combined targeted treatment of lung cancer patients with an emphasis on EGFR-mutant disease and describes findings obtained for a first-in-class agent targeting the KRASG212C mutation.

Maarten Lambrecht highlights aspects of radiobiology regarding interactions between radiotherapy and the immune system, non-invasive imaging biomarkers and trial results presented at ESMO 2020 that bear importance from a radiation oncologist’s point of view.

Paul Baas discusses the prognosis and treatment of patients with malignant mesothelioma, relating to combined modality treatment with immune checkpoint inhibitors plus chemotherapy and talks about other immunotherapeutic approaches beyond checkpoint inhibition.

The ESMO Virtual Congress 2020 has attracted more than 30,000 registrants from over 150 countries to whom content presented at more than 70 sessions has been made available.

Byoung Chul Cho • MD • PhD, Division of Medical Oncology, Yonsei Cancer Center – Yonsei University College of Medicine – Seoul, South Korea
Go to Top